Review. Anticoagulant Therapy in Sepsis. The Importance of Timing

Open access


Sepsis associated coagulopathy is due to the inflammation-induced activation of coagulation pathways concomitant with dysfunction of anticoagulant and fibrinolytic systems, leading to different degrees of haemostasis dysregulation. This response is initially beneficial, contributing to antimicrobial defence, but when control is lost coagulation activation leads to widespread microvascular thrombosis and subsequent organ failure. Large clinical trials of sepsis-related anticoagulant therapies failed to show survival benefits, but posthoc analysis of databases and several smaller studies showed beneficial effects of anticoagulants in subgroups of patients with early sepsis-induced disseminated intravascular coagulation. A reasonable explanation could be the difference in timing of anticoagulant therapy and patient heterogeneity associated with large trials. Proper selection of patients and adequate timing are required for treatment to be successful. The time when coagulation activation changes from advantageous to detrimental represents the right moment for the administration of coagulation-targeted therapy. In this way, the defence function of the haemostatic system is preserved, and the harmful effects of overwhelming coagulation activation are avoided.

1. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315:801-10. doi:

2. Copotoiu S-M, Copotoiu R. Much Ado About the New Definitions of Sepsis. J Crit Care Med. 2016;2:67-72. doi:

3. Rawal G, Kumar R, Yadav S, Singh A. Anemia in Intensive Care: A review of Current Concepts. J Crit Care Med. 2016;2:109-114. doi:

4. Semeraro N, Ammollo CT, Semeraro F, Colucci M. Sepsis, thrombosis and organ dysfunction. Thromb Res. 2012;129:290‑5. doi:

5. Levi M. The coagulant response in sepsis and inflammation. Hamostaseologie. 2010;30:10-6.

6. Wiersinga WJ, Levi M, van der Poll T: Coagulation in Sepsis. In Abraham E, Singer M, editors: Mechanisms of Sepsis-Induced Organ Dysfunction and Recovery. Berlin, Heidelberg: Springer. 2007, pp. 273-85.

7. Levi M, Poll T. Coagulation in patients with severe sepsis. Semin Thromb Hemost. 2015;41:9-15. doi:

8. Mackman N. The many faces of tissue factor. J Thromb Haemost. 2009;7 Suppl 1:136-9. doi:

9. Iba T, Nagaoka I, Boulat M. The anticoagulant therapy for sepsisassociated disseminated intravascular coagulation. Thromb Res. 2013;131:383-9. doi:

10. Pawlinski R, Mackman N. Cellular sources of tissue factor in endotoxemia and sepsis. Thromb Res. 2010;125 Suppl 1:S70-3. doi:

11. Camicia G, Pozner R, de Larranaga G. Neutrophil extracellular traps in sepsis. Shock. 2014;42:286-94. doi:

12. Allen KS, Sawheny E, Kinasewitz GT. Anticoagulant modulation of inflammation in severe sepsis. World J Crit Care Med. 2015;4:105-15. doi:

13. Prakash S, Verghese S, Roxby D, et al. Changes in fibrinolysis and severity of organ failure in sepsis: a prospective observational study using point-of-care test--ROTEM. J Crit Care. 2015;30:264-70. doi:

14. Zeerleder S, Schroeder V, Hack CE, Kohler HP, Wuillemin WA. TAFI and PAI-1 levels in human sepsis. Thromb Res. 2006;118:205-12. doi:

15. Georgescu A-M, Szederjesi J, Voidăzan S, et al. Soluble urokinase-type plasminogen activator receptor (suPAR) - a possible biomarker for bacteremia in sepsis. Romanian Review of Laboratory Medicine. 2015;23:59-73. doi:

16. Fiusa MM, Carvalho-Filho MA, Annichino-Bizzacchi JM, De Paula EV. Causes and consequences of coagulation activation in sepsis: an evolutionary medicine perspective. BMC Med. 2015;13:105. doi:

17. Toh CH, Alhamdi Y, Abrams ST. Current Pathological and Laboratory Considerations in the Diagnosis of Disseminated Intravascular Coagulation. Ann Lab Med. 2016;36:505-12. doi:

18. Robriquet L, Collet F, Tournoys A, et al. Intravenous administration of activated protein C in Pseudomonas-induced lung injury: impact on lung fluid balance and the inflammatory response. Respir Res. 2006;7:1-10. doi:

19. Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood. 2007;109:3161-72. doi:

20. Shaw AD, Vail GM, Haney DJ, Xie J, Williams MD. Severe protein C deficiency is associated with organ dysfunction in patients with severe sepsis.J Crit Care. 2011;26:539-45. doi:

21. Brunkhorst F, Sakr Y, Hagel S, Reinhart K. Protein C concentrations correlate with organ dysfunction and predict outcome independent of the presence of sepsis. Anesthesiology. 2007;107:15-23. doi:

22. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344: 699-709. doi:

23. Abraham E, Laterre P-F, Garg R, et al. Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low Risk of Death. N Engl J Med. 2005;353:1332-41. doi:

24. Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012;366:2055-64. doi:

25. Marti-Carvajal AJ, Sola I, Gluud C, Lathyris D, Cardona AF. Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients. Cochrane Database Syst Rev. 2012;12:Cd004388. doi:

26. Casserly B, Gerlach H, Phillips GS, et al. Evaluating the use of recombinant human activated protein C in adult severe sepsis: results of the Surviving Sepsis Campaign. Crit Care Med. 2012;40:1417-26. doi:

27. Dhainaut JF, Yan SB, Joyce DE, et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost. 2004;2:1924-33. doi:

28. Iba T, Gando S, Thachil J. Anticoagulant therapy for sepsisassociated disseminated intravascular coagulation: the view from Japan. J Thromb Haemost. 2014;12:1010-9. doi:

29. Aoki N, Matsuda T, Saito H, et al. A Comparative Double-Blind Randomized Trial of Activated Protein C and Unfractionated Heparin in the Treatment of Disseminated Intravascular Coagulation. Int J Hematol. 2002;75:540-7.

30. Levi M, van der Poll T. The role of natural anticoagulants in the pathogenesis and management of systemic activation of coagulation and inflammation in critically ill patients. Semin Thromb Hemost. 2008;34:459-68. doi:

31. Minnema MC, Chang AC, Jansen PM, et al. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood. 2000;95:1117-23.

32. Chappell D, Jacob M, Hofmann-Kiefer K, et al. Antithrombin reduces shedding of the endothelial glycocalyx following ischaemia/reperfusion. Cardiovasc Res. 2009;83:388-96. doi:

33. Iba T, Gando S, Murata A, et al. Predicting the severity of systemic inflammatory response syndrome (SIRS)-associated coagulopathy with hemostatic molecular markers and vascular endothelial injury markers. J Trauma. 2007;63:1093-8. doi:

34. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001;286:1869-78.

35. Kienast J, Juers M, Wiedermann CJ, et al. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost. 2006;4:90-7. doi:

36. Wiedermann CJ, Kaneider NC. A systematic review of antithrombin concentrate use in patients with disseminated intravascular coagulation of severe sepsis. Blood Coagul Fibrinolysis. 2006;17:521-6. doi:

37. Iba T, Saitoh D, Wada H, Asakura H. Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a secondary survey. Crit Care. 2014;18:497. doi:

38. Iba T, Gando S, Saitoh D, et al. Efficacy and Bleeding Risk of Antithrombin Supplementation in Patients With Septic Disseminated Intravascular Coagulation. Clin Appl Thromb Hemost. 2016. doi:

39. Gando S, Saitoh D, Ishikura H, et al. A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Crit Care. 2013;17:R297. doi:

40. Iba T, Saitoh D, Gando S, Thachil J. The usefulness of antithrombin activity monitoring during antithrombin supplementation in patients with sepsis-associated disseminated intravascular coagulation. Thromb Res. 2015;135:897-901. doi:

41. Allingstrup M, Wetterslev J, Ravn FB, Moller AM, Afshari A. Antithrombin III for critically ill patients. Cochrane Database Syst Rev. 2016;2:Cd005370. doi:

42. Iba T, Thachil J. Present and future of anticoagulant therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation: a perspective from Japan. Int J Hematol. 2016;103:253-61. doi:

43. Oda S, Aibiki M, Ikeda T, et al. The Japanese guidelines for the management of sepsis. J Intensive Care. 2014;2:55. doi:

44. King EG, Bauza GJ, Mella JR, Remick DG. Pathophysiologic mechanisms in septic shock. Lab Invest. 2014;94:4-12. doi:

45. Saito H, Maruyama I, Shimazaki S, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007;5:31-41. doi:

46. Aikawa N, Shimazaki S, Yamamoto Y, et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock. 2011;35:349-54. doi:

47. Vincent JL, Ramesh MK, Ernest D, et al. A randomized, doubleblind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med. 2013;41:2069-79. doi:

48. Hoppensteadt D, Tsuruta K, Cunanan J, et al. Thrombin generation mediators and markers in sepsis-associated coagulopathy and their modulation by recombinant thrombomodulin. Clin Appl Thromb Hemost. 2014;20:129-35. doi:

49. Kato T, Sakai T, Kato M, et al. Recombinant human soluble thrombomodulin administration improves sepsis-induced disseminated intravascular coagulation and mortality: a retrospective cohort study. Thromb J. 2013;11:3. doi:

50. Yamakawa K, Aihara M, Ogura H, et al. Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis. J Thromb Haemost. 2015;13:508-19. doi:

51. Maroney SA, Hansen KG, Mast AE. Cellular expression and biological activities of alternatively spliced forms of tissue factor pathway inhibitor. Curr Opin Hematol. 2013;20:403-9. doi:

52. Lupu C, Herlea O, Tang H, Lijnen RH, Lupu F. Plasmin-dependent proteolysis of tissue factor pathway inhibitor in a mouse model of endotoxemia. J Thromb Haemost. 2013;11:142-8. doi:

53. Tang H, Ivanciu L, Popescu N, et al. Sepsis-induced coagulation in the baboon lung is associated with decreased tissue factor pathway inhibitor. Am J Pathol.. 2007;171:1066-77. doi:

54. Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003;290:238-47. doi:

55. Wunderink RG, Laterre PF, Francois B, et al. Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2011;183:1561-8. doi:

56. Polderman KH, Girbes AR. Drug intervention trials in sepsis: divergent results. Lancet. 2004;363:1721-3. doi:

57. Levi M, Levy M, Williams MD, et al. Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am J Respir Crit Care Med. 2007;176:483-90. doi:

58. Jaimes F, De La Rosa G, Morales C, et al. Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study). Crit Care Med. 2009;37:1185-96. doi:

59. Liu XL, Wang XZ, Liu XX, et al. Low-dose heparin as treatment for early disseminated intravascular coagulation during sepsis: A prospective clinical study. Exp Ther Med. 2014;7:604-8. doi:

60. Wang C, Chi C, Guo L, et al. Heparin therapy reduces 28-day mortality in adult severe sepsis patients: a systematic review and meta-analysis. Critical care. 2014;18:563. doi:

61. Zarychanski R, Abou-Setta AM, Kanji S, et al. The efficacy and safety of heparin in patients with sepsis: a systematic review and metaanalysis. Crit Care Med. 2015;43:511-8. doi:

62. Houston BL, Dwivedi DJ, Grin P, et al. Biological Rational for the Use of Heparin in Septic Shock: Translational Data from the Halo Pilot RCT. Blood. 2015;126:2336.

63. Wildhagen KC, Garcia de Frutos P, Reutelingsperger CP, et al. Nonanticoagulant heparin prevents histone-mediated cytotoxicity in vitro and improves survival in sepsis. Blood. 2014;123:1098-101. doi:

Journal Information


All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 110 110 39
PDF Downloads 37 37 17